Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia
Mycoses, 05/04/2012AlBadriyeh D et al. –
Caspofungin appears to have a higher probability of having cost–savings than voriconazole for empirical therapy. The difference between the two medications does not seem to be statistically significant however.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.